Molecular typing of clinical isolates of Cryptococcus neoformans/Cryptococcus gattii species complex from Northeast Mexico
Language English Country United States Media print-electronic
Document type Journal Article
PubMed
26109075
DOI
10.1007/s12223-015-0409-8
PII: 10.1007/s12223-015-0409-8
Knihovny.cz E-resources
- MeSH
- Antifungal Agents pharmacology MeSH
- Cryptococcus gattii classification genetics isolation & purification MeSH
- Cryptococcus neoformans classification genetics isolation & purification MeSH
- DNA Fingerprinting MeSH
- Adult MeSH
- Cryptococcosis epidemiology microbiology MeSH
- Middle Aged MeSH
- Humans MeSH
- Microbial Sensitivity Tests MeSH
- Adolescent MeSH
- Young Adult MeSH
- Molecular Epidemiology MeSH
- Molecular Typing * MeSH
- Mycological Typing Techniques * MeSH
- Hospitals MeSH
- Polymerase Chain Reaction MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Mexico epidemiology MeSH
- Names of Substances
- Antifungal Agents MeSH
Cryptococcosis is caused by members of the Cryptococcus neoformans/Cryptococcus gattii species complex. Based on molecular identification, these two species have been further differentiated into molecular types. The aim of this work was to characterize clinical cryptococcal isolates recovered from six hospitals in Northeast Mexico from 1995 to 2011. One hundred and sixty-six isolates, which were characterized by biochemical tests and in vitro susceptibility to amphotericin B, fluconazole, and voriconazole, and M13 PCR fingerprinting, were included in this study. Utilizing phenotypic tests, 153 isolates (92.16 %) were identified as C. neoformans and 13 (7.83 %) as C. gattii. All isolates were susceptible to all antifungals tested. Employing M13 PCR fingerprinting, eight molecular types were detected. VNI was the most common genotype (124 cases; 74.6 %), followed by VNII (15 cases; 9 %), VNIII (8 cases; 4.8 %), VNIV (6 cases; 3.6 %), VGI (6 cases; 3.6 %), VGII (3 cases; 1.8 %), and VGIII and VGIV (2 cases, 1.2 % each). We confirm the presence of C. gattii in clinical isolates in Northeast Mexico, and a high clonal diversity in the studied strains of C. neoformans/C. gattii species complex.
See more in PubMed
J Clin Microbiol. 1994 May;32(5):1188-92 PubMed
Curr Genet. 1997 Sep;32(3):203-8 PubMed
J Clin Microbiol. 1997 Sep;35(9):2243-51 PubMed
Med Mycol. 2009 Nov;47(7):713-21 PubMed
Can Vet J. 2002 Oct;43(10):792-4 PubMed
Med Mycol. 2012 Apr;50(3):328-32 PubMed
Mycoses. 1991 Sep-Oct;34(9-10):377-9 PubMed
Nature. 2005 Oct 27;437(7063):1360-4 PubMed
Antimicrob Agents Chemother. 2010 Dec;54(12):5139-45 PubMed
Antimicrob Agents Chemother. 2001 Nov;45(11):3065-9 PubMed
Springerplus. 2013 Nov 23;2:632 PubMed
J Clin Microbiol. 2010 Nov;48(11):4115-20 PubMed
Eur J Clin Microbiol Infect Dis. 2004 Jun;23(6):506-8 PubMed
Emerg Infect Dis. 2003 Feb;9(2):189-95 PubMed
Mycopathologia. 2013 Oct;176(3-4):267-72 PubMed
Med Mycol. 2004 Jun;42(3):229-38 PubMed
Infect Immun. 1989 Sep;57(9):2624-7 PubMed
Infect Dis Clin North Am. 2006 Sep;20(3):507-44, v-vi PubMed
Emerg Infect Dis. 2007 Jan;13(1):51-7 PubMed
J Antimicrob Chemother. 2005 Dec;56(6):1144-7 PubMed
Mycoses. 2002 Nov;45(9-10):378-83 PubMed
Clin Microbiol Rev. 1995 Oct;8(4):515-48 PubMed
Scientifica (Cairo). 2013;2013:675213 PubMed
Rev Iberoam Micol. 2008 Mar;25(1):S4-12 PubMed
PLoS One. 2013 Aug 07;8(8):e71148 PubMed
BMC Infect Dis. 2010 Oct 04;10:289 PubMed
Clin Infect Dis. 2010 Feb 1;50(3):338-44 PubMed
J Clin Microbiol. 2012 Jun;50(6):1918-26 PubMed
PLoS One. 2013 Apr 17;8(4):e61921 PubMed
Mycoses. 2012 May;55(3):e145-50 PubMed
Clin Microbiol Infect. 2008 Jul;14(7):727-30 PubMed
Mycopathologia. 2010 Oct;170(4):279-85 PubMed
Rev Iberoam Micol. 1999 Mar;16(1):40-2 PubMed
Am J Epidemiol. 1977 Jun;105(6):582-6 PubMed
J Clin Microbiol. 2005 May;43(5):2163-7 PubMed
J Antimicrob Chemother. 2003 Oct;52(4):683-6 PubMed
J Clin Microbiol. 2010 Feb;48(2):539-44 PubMed
Clin Microbiol Infect. 2013 Aug;19(8):763-9 PubMed
Lancet Infect Dis. 2005 Sep;5(9):530-1 PubMed
J Clin Microbiol. 1999 Mar;37(3):715-20 PubMed
Med Mycol. 2008 Nov;46(7):685-96 PubMed
